Richard Bernstein Advisors LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 5.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 103,670 shares of the company’s stock after purchasing an additional 5,356 shares during the quarter. Richard Bernstein Advisors LLC’s holdings in Johnson & Johnson were worth $12,579,000 at the end of the most recent quarter.
A number of other large investors also recently added to or reduced their stakes in JNJ. Financial Gravity Wealth Inc. bought a new stake in Johnson & Johnson in the 1st quarter valued at $105,000. WP Advisors LLC bought a new stake in Johnson & Johnson in the 2nd quarter valued at $108,000. FNY Investment Advisers LLC bought a new stake in Johnson & Johnson in the 2nd quarter valued at $117,000. Fusion Family Wealth LLC increased its holdings in Johnson & Johnson by 621.4% in the 2nd quarter. Fusion Family Wealth LLC now owns 1,010 shares of the company’s stock valued at $123,000 after buying an additional 870 shares during the period. Finally, Live Your Vision LLC increased its holdings in Johnson & Johnson by 58.3% in the 2nd quarter. Live Your Vision LLC now owns 1,363 shares of the company’s stock valued at $172,000 after buying an additional 502 shares during the period. Hedge funds and other institutional investors own 66.51% of the company’s stock.
In other news, CAO Ronald A. Kapusta sold 8,441 shares of the company’s stock in a transaction dated Thursday, November 8th. The shares were sold at an average price of $145.15, for a total value of $1,225,211.15. Following the sale, the chief accounting officer now owns 17,284 shares of the company’s stock, valued at approximately $2,508,772.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Peter Fasolo sold 166,695 shares of the stock in a transaction dated Tuesday, December 4th. The stock was sold at an average price of $146.41, for a total transaction of $24,405,814.95. Following the sale, the vice president now directly owns 155,540 shares in the company, valued at approximately $22,772,611.40. The disclosure for this sale can be found here. In the last ninety days, insiders sold 510,544 shares of company stock worth $74,414,877. 0.22% of the stock is owned by insiders.
JNJ opened at $145.43 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.72. Johnson & Johnson has a twelve month low of $118.62 and a twelve month high of $148.99. The stock has a market capitalization of $391.46 billion, a PE ratio of 19.92, a PEG ratio of 2.28 and a beta of 0.59.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 16th. The company reported $2.05 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.03 by $0.02. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. The business had revenue of $20.35 billion for the quarter, compared to analyst estimates of $20.05 billion. During the same quarter in the prior year, the firm earned $1.90 EPS. The firm’s quarterly revenue was up 3.6% compared to the same quarter last year. Analysts expect that Johnson & Johnson will post 8.16 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 11th. Stockholders of record on Tuesday, November 27th will be issued a $0.90 dividend. This represents a $3.60 annualized dividend and a dividend yield of 2.48%. The ex-dividend date is Monday, November 26th. Johnson & Johnson’s payout ratio is 49.32%.
Several equities research analysts have issued reports on JNJ shares. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $165.00 price target on the stock in a report on Tuesday, November 20th. HC Wainwright reissued a “buy” rating on shares of Johnson & Johnson in a report on Wednesday, October 17th. Credit Suisse Group set a $149.00 price target on shares of Johnson & Johnson and gave the company a “buy” rating in a report on Sunday, October 14th. Citigroup boosted their price target on shares of Johnson & Johnson from $137.00 to $148.00 and gave the company a “neutral” rating in a report on Monday, October 22nd. Finally, Wells Fargo & Co reissued an “outperform” rating and issued a $160.00 price target on shares of Johnson & Johnson in a report on Friday, September 14th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have issued a buy rating to the stock. Johnson & Johnson has a consensus rating of “Hold” and a consensus price target of $143.90.
ILLEGAL ACTIVITY WARNING: “Johnson & Johnson (JNJ) Shares Bought by Richard Bernstein Advisors LLC” was published by American Banking News and is the property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2018/12/08/johnson-johnson-jnj-shares-bought-by-richard-bernstein-advisors-llc.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
See Also: How dollar cost averaging works
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.